News | January 26, 2012

Heart Hospital of Austin Among First Approved for TAVR Since FDA Clearance


January 26, 2012 — Heart Hospital of Austin opened a heart valve clinic, the first of its kind in the region. The clinic gives new hope to patients with severe aortic stenosis who were previously considered inoperable, offering a multidisciplinary approach to evaluating such cases. Interventional cardiologists and cardiac surgeons at the clinic will collaboratively identify patients who may be eligible for a new, catheter-based valve replacement procedure -- transcatheter aortic valve replacement (TAVR) -- instead of traditional, open-chest procedures. Heart Hospital of Austin is among the first sites in the nation to receive this TAVR technology since the U.S. Food and Drug Administration (FDA) approved it in November 2011.

"This is truly a collaborative approach to valve replacement that will provide another option for patients who are not candidates for open-chest surgery due to advanced age, or because they are too ill or suffering from additional medical conditions," Faraz Kerendi, M.D., a cardiothoracic surgeon at Cardiothoracic and Vascular Surgeons, which practices at Heart Hospital of Austin, said. "Prior to this procedure … [patients] were often given only months to live."

Severe aortic stenosis is a condition in which the opening of the aortic valve becomes narrow, restricting blood flow from the heart.

"Over time, the valve can become calcified, preventing it from opening and releasing the blood properly," Juhana Karha, M.D., an interventional cardiologist at Heart Hospital of Austin and with Austin Heart, said. "Open-chest surgery is the traditional treatment method for this condition, but catheter-based valve replacement gives hope to patients who cannot undergo surgery for a variety of reasons."

Symptoms of severe aortic stenosis include chest pain and chest pressure. It can also cause blood to back up into the lungs, resulting in shortness of breath and other breathing problems. Left untreated, this condition is often fatal.

Transcatheter aortic valve replacement consists of inserting a valve — which has been developed to shrink down to the size of a pencil —  through the groin via catheter, up to the aorta. After the catheter is advanced through the aorta and aortic valve, it is positioned and then opened with a balloon.

Transcatheter aortic valve replacement results in a shorter recovery time — one to two weeks, versus six to eight weeks for traditional surgery — and a much smaller incision. More importantly, it prevents the need for physicians to utilize a heart bypass machine. This new technology allows the patient's heart to beat on its own throughout the entire procedure.

The first transcatheter aortic valve replacement procedure is expected to take place in February.

For more information: www.hearthospitalofaustin.com, www.austinheart.com


Related Content

News | Heart Valve Technology

Sept. 1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid ...

Home September 04, 2024
Home
News | Heart Valve Technology

June 27, 2024 — The sheer scale of undiagnosed heart valve disease in our aging population has been revealed for the ...

Home June 27, 2024
Home
News | Heart Valve Technology

June 21, 2024 — UC San Francisco interventional cardiologists and interventional echocardiographers recently performed ...

Home June 21, 2024
Home
News | Heart Valve Technology

June 10, 2024 — Atrium Health Sanger Heart & Vascular Institute has successfully completed the first commercial ...

Home June 10, 2024
Home
News | Heart Valve Technology

April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop ...

Home April 17, 2024
Home
News | Heart Valve Technology

April 1, 2024 — Roughly 25,000 Americans die each year from valvular heart disease, but researchers from Rutgers Health ...

Home April 01, 2024
Home
News | Heart Valve Technology

January 4, 2024 — Findings from a published case series research letter by the Henry Ford Health Structural Heart ...

Home January 04, 2024
Home
News | Heart Valve Technology

December 22, 2023 — TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of ...

Home December 22, 2023
Home
News | Heart Valve Technology

December 18, 2023 — Death rates related to infective endocarditis declined in most adults across the U.S. within the ...

Home December 18, 2023
Home
News | Heart Valve Technology

December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aortic valve replacement ...

Home December 12, 2023
Home
Subscribe Now